What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?

References

• Chetwynd J, Brunton C, Blank M et al. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme. NZ Med J 1995; 108: 364–6.
   Google Scholar
• Carter H, Robinson G, Hanlon C et al. Prevalence of hepatitis B and C infection in a methadone clinic popula- tion: implications for hepatitis B vaccination. NZ Med J 2001; 114: 324–6.
   Google Scholar
• Nesdale A, Baker M, Gane E et al. Hepatitis C infection in New Zealand: estimating the current and future prevalence and impact. Wellington: Institute of Environmental Science and Research Ltd, 2000.
   Google Scholar
• Sellman JD, Harvey M, Deering DE et al. South Island Methadone Project Report. Christchurch, New Zealand: National Centre for Treatment Development (Alcohol, Drugs and Addiction), 2001.
   Google Scholar
• Crofts N, Wodak A. Gaining control of the hepatitis C virus epidemic in Australia. In: Crofts N, Dore G, Locarnini S, eds. Hepatitis C: an Australian perspective, chapter 22. Melbourne: IP Communications, 2001.
   Google Scholar
• National Institutes of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997;26(Suppl.1):S2– 10.
   Google Scholar
• Dore GM, Walker JD, Paice JR et al. Methadone maintenance treatment: outcomes from the Otago metha- done Programme. NZ Med J 1999; 112:442–5.
   PubMedGoogle Scholar
• Blakely T, Salmond C, Tobias M. Hepatitis B virus carrier prevalance in New Zealand: population estimates using the 1987 police and customs personnel; survey. NZ Med J 1998; 111: 142–4.
   Google Scholar
• Gane E. Chronic hepatitis B virus infection in South Auckland. NZ Med J 1998; 111: 120–3.
   Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alpha 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1485–99.
   Google Scholar
• McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–99.
   Google Scholar
• Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32.
   Google Scholar
• Heathcote EJ, Shiffman ML, Cooksley GE et al. Peginter- feron alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673–80.
   PubMed Web of Science ®Google Scholar
• Glue P, Rouzier-Panis R, Raffanel C. A dose ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000; 32: 647–53.
   Google Scholar
• Zeuzem S, Feinman V, Rasenack J et al. Peginterferon alfa- 2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–72.
   Google Scholar
• Manns MP, McHutchison JG, Gordon SC et al. Peginter- feron alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958 – 65.
   PubMed Web of Science ®Google Scholar
• Davis GL Treatment of chronic hepatitis C. Br Med J 2001; 323: 1141–2.
   Google Scholar
• Gane E. Current management of hepatitis C in New Zealand. Keynote address, Cutting Edge Conference on Alcohol Drug and Addictive Disorders, Napier, New Zealand, 2001.
   Google Scholar
• Joe GW, Lehman W, Simpson DD. Addict death rates during a four year posttreatment follow-up. Am J Public Health 1982; 72: 703–9.
   Google Scholar
• Sheerin IG, Green FT, Sellman JD. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand. Alcohol Drug Rev 2003; 22: 159–67.
   Google Scholar
• Caplehorn JRM, Dalton MSYN, Haldar F et al. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse 1996; 31: 177–96.
   Google Scholar
• Barnett PG. The cost-effectiveness of methadone main- tenance as a health care intervention. Addiction 1999; 94: 479–88.
   Google Scholar
• Dukes PD, Robinson GM, Robinson BJ. Mortality of intravenous drug users: attenders of the Wellington drug clinic, 1972 – 89. Drug Alcohol Rev 1992; 11: 197–201.
   Google Scholar
• Ministry of Health. Mortality and demographic data 1996 [this publication uses the Australian version of ICD 9- CMA-II]. Wellington: Ministry of Health, 1997.
   Google Scholar
• Durie MH. Whaiora, Maori health development, 2nd edn. Auckland: Oxford University Press, 1998.
   Google Scholar
• Freeman AJ, Dore GJ, Law MG et al. Estimating progres- sion to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809–16.
   Google Scholar
• Law MG. Modelling the hepatitis C virus epidemic in Australia. J Gastroenterol Hepatol 1999; 14: 1100–7.
   Google Scholar
• Wong JB, Poynard T, Ling MH et al. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastro- enterol 2000; 95: 1524–30.
   Google Scholar
• Kim WR, Poterucha JJ, Hermans JE et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866–74.
   Google Scholar
• Bennett WG, Inoue Y, Beck JR. Estimates of the cost- effectiveness of a single course of interferon alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855–65.
   Google Scholar
• Seef LB. Natural history of hepatitis C. Hepatology 1997;26(Suppl. 1): S21– 8.
   Google Scholar
• Dolan M. The hepatitis C handbook. London: Catalyst Press, 1997.
   Google Scholar
• Tong MJ, El-Farra NS, Reikes AR et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–6.
   Google Scholar
• Szeto KL, Devlin NJ. The cost-effectiveness of mammo- graphy screening: evidence from a microsimulation model for New Zealand. Health Policy 1996; 38: 101–15.
   Google Scholar
• Croxson BE, Ashton T. A cost-effectiveness analysis of end stage renal failure. NZ Med J 1990; 103: 171–4.
   PubMed Web of Science ®Google Scholar
• Oppenheimer E, Tobutt C, Taylor C et al. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction 1994; 89: 1299–308.
   Google Scholar
• Watterson O, Simpson DD, Sells SB. Death rates and causes of death among opioid addicts in community treatment programs during 1970 – 1973. Am J Drug Alcohol Abuse 1975; 2: 99–111.
   Google Scholar
• Segest E, Mygind O, Bay H. The influence of prolonged stable methadone maintenance treatment on mortality and employment: an 8 year follow-up. Int J Addict 1990; 25: 53–63.
   Google Scholar
• Ward J, Mattick RP, Hall W, eds. Methadone maintenance treatment and other opioid replacement therapies. Amster- dam: Harwood Academic, 1998.
   Google Scholar